The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Abiraterone 250 mg film-coated tablets

250 milligram(s) Film-coated tablet

Rowex LtdPA0711/304/001

Main Information

Trade NameAbiraterone 250 mg film-coated tablets
Active SubstancesAbiraterone acetate
Strength250 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderRowex Ltd
Licence NumberPA0711/304/001

Group Information

ATC CodeL02BX03 abiraterone


Licence Issued18/06/2021
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back